Table 1.
Description of bacterial isolates per species including departments, source material and resistance patterns against selected antibiotics in setting n.1 (30 August–30 September 2021).
| Species | S. aureus | E. faecium | K. pneumoniae | P. aeruginosa | E. coli |
|---|---|---|---|---|---|
| Number of bacterial isolates Total n = 145 |
20 | 10 | 45 | 27 | 43 |
| Department | |||||
| Medicine | 60% (12/20) | 60% (6/10) | 40% (18/45) | 44% (12/27) | 55.8% (24/43) |
| Intensive care unit | 10% (2/20) | 20% (2/10) | 40% (18/45) | 33.3% (9/27) | 11.6% (5/43) |
| Infectious disease | 15% (3/20) | 20% (2/10) | 15.5% (7/45) | 18.5% (5/27) | 23.2% (10/43) |
| Neonatology | 15% (3/20) | 0% | 4.4% (2/45) | 3.7% (1/27) | 9.3% (4/43) |
| Source material | |||||
| Urine | 5% (1/20) | 20% (2/10) | 46.6% (21/45) | 14.8% (4/27) | 67.4% (29/43) |
| Blood | 30% (6/20) | 30% (3/10) | 11% (5/45) | 22.2% (6/27) | 18.6% (8/43) |
| Respiratory | 25% (5/20) | 0% | 22.2% (10/45) | 29.6% (8/27) | 2.3% (1/43) |
| Wound | 40% (8/20) | 10% (1/10) | 13.3% (6/45) | 18.5% (5/27) | 4.6% (2.43) |
| Venous catheter | 0% | 40% (4/10) | 6.7% (3/45) | 7.4% (2/27) | 7.0% (3/43) |
| Resistance to antibiotics | |||||
| 40% (8/20) methicillin-resistant S. aureus (MRSA) | 30% (3/10) vancomycin-resistant E. faecium (VRE) | 42.2% (19/45) multidrug resistance (MDR) | 11% (3/27) MDR | 30.2% (13/43) extended spectrum beta lactamase (ESBL) | |
| Benzylpenicillin | 65% (13/20) | ||||
| Ampicillin | 66.6% (26/39) | ||||
| Amoxicillin–Clavulanic Acid | 100% (10/10) | 60% (27/45) | 46.5% (20/43) | ||
| Piperacillin–tazobactam | 55.5% (25/45) | 22.2% (6/27) | 7.0% (3/43) | ||
| Cefotaxime | 51.1% (23/45) | 30.2% (13/43) | |||
| Ceftazidime | 53.3% (24/45) | 25.9% (7/27) | 18.6% (8/43) | ||
| Carbapenems (imipenem or meropenem) | 100% (10/10) | 42.2% (19/45) | 25.9% (7/27) | 2% (1/43) | |
| Ceftazidime–avibactam | 26.6% (12/45) | 0% | |||
| Clindamycin | 50% (10/20) | ||||
| Amikacin | 37.7% (17/45) | 4.6% (2/43) | |||
| Gentamycin | 20% (4/20) | 35.5% (16/45) | 18.6% (8/43) | ||
| Fluoroquinolones (ciprofloxacin or levofloxacin) | 30% (6/20) | 70% (7/10) | 44.4% (20/45) | 18.5% (5/27) | 41.8% (18/43) |
| Linezolid | 0% | 0% | |||
| Vancomycin | 0% | 30% (3/10) | |||
| Daptomycin | 0% | 0% | |||
| Tigecycline | 0% | 10% (1/10) | |||
| Tetracycline | 20% (4/20) | ||||
| Trimethoprim–sulfamethoxazole | 0% | 44.4% (20/45) | |||
| Nitrofurantoin | 0% | ||||
| Colistin | 13.3% (6/45) | 0% | |||